Clinical Trial Update: Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial of lurbinectedin (PM01183) in platinum-resistant ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: PharmaMar | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-03-05